title: Ibrutinib antagonizes rituximab-dependent NK cell-mediated cytotoxicity.
authors.affiliation: Division of Oncology, Department of Medicine, Stanford University Cancer Institute, Stanford, CA.
authors.forename: Holbrook E
authors.initials: HE
authors.lastname: Kohrt
authors.forename: Idit
authors.initials: I
authors.lastname: Sagiv-Barfi
authors.forename: Sarwish
authors.initials: S
authors.lastname: Rafiq
authors.forename: Sarah E M
authors.initials: SE
authors.lastname: Herman
authors.forename: Jonathon P
authors.initials: JP
authors.lastname: Butchar
authors.forename: Carolyn
authors.initials: C
authors.lastname: Cheney
authors.forename: Xiaoli
authors.initials: X
authors.lastname: Zhang
authors.forename: Joseph J
authors.initials: JJ
authors.lastname: Buggy
authors.forename: Natarajan
authors.initials: N
authors.lastname: Muthusamy
authors.forename: Ronald
authors.initials: R
authors.lastname: Levy
authors.forename: Amy J
authors.initials: AJ
authors.lastname: Johnson
authors.forename: John C
authors.initials: JC
authors.lastname: Byrd
mesh_terms: D000225:Adenine / Q000031:analogs & derivatives; D000077329:Agammaglobulinaemia Tyrosine Kinase; D000818:Animals; D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage*; D000920:Antibody-Dependent Cell Cytotoxicity / Q000187:drug effects*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects; D002460:Cell Line; D045744:Cell Line, Tumor; D004347:Drug Interactions; D006801:Humans; D007694:Killer Cells, Natural / Q000187:drug effects* / Q000276:immunology* / Q000378:metabolism; D016393:Lymphoma, B-Cell / Q000188:drug therapy / Q000276:immunology; D051379:Mice; D010880:Piperidines; D047428:Protein Kinase Inhibitors / Q000494:pharmacology; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D011720:Pyrazoles / Q000008:administration & dosage* / Q000009:adverse effects*; D011743:Pyrimidines / Q000008:administration & dosage* / Q000009:adverse effects*; D000069283:Rituximab
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D010880:Piperidines; D047428:Protein Kinase Inhibitors; D011720:Pyrazoles; D011743:Pyrimidines; C551803:ibrutinib; D000069283:Rituximab; D011505:Protein-Tyrosine Kinases; D000077329:Agammaglobulinaemia Tyrosine Kinase; D000225:Adenine